title: [Evaluation of ventricular function in patients treated with mitoxantrone and 4'-epidoxorubicin].
abstract: Serial assessment of ventricular function by means of radionuclide angiography was performed in previously untreated patients with lymphoproliferative diseases who received either 4'epidoxorubicin or mitoxantrone for longer than 6 months. No changes were observed in left ventricular function in patients received mitoxantrone at doses ranged 90 to 165 mg (mean 113 mg). Three patients (7%) in 4'epidoxorubicin group showed less than or equal to 10% drop in left ventricular ejection, but without clinical manifestations. The doses in this group were 420 to 810 mg (mean 610 mg). We felt that patients without high-risk factors (radiotherapy to mediastinum or previously anthracycline therapy) could be treated with high doses of both drugs and that radionuclide angiography is a useful method for monitoring cardiotoxicity of antineoplastic drugs.
authors.affiliation: Departamento de Hematología, Centro Médico Nacional I.M.S.S., México, D.F.
authors.forename: A
authors.initials: A
authors.lastname: Avilés
authors.forename: J C
authors.initials: JC
authors.lastname: Díaz-Maqueo
authors.forename: N
authors.initials: N
authors.lastname: Arévila-Ceballos
authors.forename: R
authors.initials: R
authors.lastname: García Fernández
authors.forename: D
authors.initials: D
authors.lastname: López-Vancell
authors.forename: V
authors.initials: V
authors.lastname: Torras
mesh_terms: D009202:Cardiomyopathies / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000503:physiopathology; D015251:Epirubicin / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D008942:Mitoxantrone / Q000009:adverse effects* / Q000494:pharmacology; D011877:Radionuclide Imaging; D013318:Stroke Volume / Q000187:drug effects*
chemical_list: D015251:Epirubicin; D008942:Mitoxantrone
vernacular_title: Valoración de la función ventricular en pacientes tratados con mitoxantrone y 4'epidoxorubicina.